Alnylam Pharmaceuticals (ALNY) Stock Price, News & Analysis

Company Overview

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing. Notable approved products include patisiran (Onpattro) for hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy, givosiran (Givlaari) for acute hepatic porphyria, lumasiran (Oxlumo) for primary hyperoxaluria type 1 and vutrisiran (Amvuttra) as an additional therapeutic option for ATTR-related disease. The company also maintains a diverse clinical-stage pipeline addressing genetic, cardio-metabolic and liver-related disorders, with programs in various stages of development aimed at expanding the reach of RNAi medicines.

Headquartered in Cambridge, Massachusetts, Alnylam operates internationally and has pursued regulatory approvals and commercial launches in multiple regions, including the United States and Europe. The company supports commercialization through its own commercial organization and through partnerships designed to extend geographic reach and accelerate development. Manufacturing strategy combines in-house capabilities and contract manufacturing to supply both clinical programs and marketed products.

As a commercial-stage, research-driven biotechnology company, Alnylam’s business model emphasizes platform innovation, clinical development and patient access. Its work centers on leveraging RNAi as a modality to address unmet medical needs, particularly in rare genetic diseases, while exploring broader indications where targeted gene silencing can offer therapeutic benefit. The company’s ongoing efforts include advancing late-stage programs, expanding indications for approved medicines and optimizing delivery technologies to broaden the applicability of RNAi therapeutics.

Key Stats

• Today's Range: $284.38 to $294.93
• 50-Day Range: $284.84 to $339.41
• 52-Week Range: $284.19 to $495.55
• Volume: 769,853 shs
• Average Volume: 1.12 million shs
• Market Capitalization: $39.29 billion
• P/E Ratio: 80.41
• Dividend Yield: N/A
• Price Target: $463.13
• Consensus Rating: Moderate Buy

Alnylam Pharmaceuticals Stock Analysis - MarketRank™

Alnylam Pharmaceuticals scored higher than 91% of companies evaluated by MarketBeat, and ranked 50th out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Alnylam Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.81, and is based on 1 strong buy rating, 19 buy ratings, 6 hold ratings, and no sell ratings.

Upside Potential

Alnylam Pharmaceuticals has a consensus price target of $463.13, representing about 57.4% upside from its current price of $294.30.

Amount of Analyst Coverage

Alnylam Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 39.54%

Earnings Growth

Earnings for Alnylam Pharmaceuticals are expected to grow by 39.54% in the coming year, from $7.36 to $10.27 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Alnylam Pharmaceuticals is 80.41, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 44.39.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alnylam Pharmaceuticals is 80.41, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 20.78.

Price to Book Value per Share Ratio

Alnylam Pharmaceuticals has a P/B Ratio of 36.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.61% of the float of Alnylam Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Alnylam Pharmaceuticals has a short interest ratio ("days to cover") of 4.02.

Change versus previous month

Short interest in Alnylam Pharmaceuticals has recently decreased by 5.18%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alnylam Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Alnylam Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 0.79

News Sentiment

Alnylam Pharmaceuticals has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 17 news articles for Alnylam Pharmaceuticals this week, compared to 10 articles on an average week.

Search Interest

Only 9 people have searched for ALNY on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

7 people have added Alnylam Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Alnylam Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,930,337.00 in company stock.

Percentage Held by Insiders

0.86% of the stock of Alnylam Pharmaceuticals is held by insiders.

Percentage Held by Institutions

92.97% of the stock of Alnylam Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 4/30/2026
• Today: 5/19/2026
• AGM 2026: 5/20/2026
• Goldman Sachs 47th Annual Global Healthcare Conference 2026: 6/09/2026
• Next Earnings (Estimated): 7/30/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ALNY
• CIK: 1178670
• Web: www.alnylam.com
• Phone: (617) 551-8200
• Fax: 617-551-8101
• Employees: 2,770
• Year Founded: 2002

Price Target and Rating

• Average Price Target for Alnylam Pharmaceuticals: $463.13
• High Price Target: $566.00
• Low Price Target: $330.00
• Potential Upside/Downside: +57.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.81
• Research Coverage: 26 Analysts

Profitability

• EPS (Trailing Twelve Months): $3.66
• Trailing P/E Ratio: 80.41
• Forward P/E Ratio: 39.99
• P/E Growth: N/A
• Net Income: $313.75 million
• Net Margins: 11.72%
• Pretax Margin: 12.76%
• Return on Equity: 85.76%
• Return on Assets: 10.32%

Debt

• Debt-to-Equity Ratio: 0.94
• Current Ratio: 3.13
• Quick Ratio: 3.06

Sales & Book Value

• Annual Sales: $3.71 billion
• Price / Sales: 10.58
• Cash Flow: $2.87 per share
• Price / Cash Flow: 102.38
• Book Value: $8.05 per share
• Price / Book: 36.56

Miscellaneous

• Outstanding Shares: 133,510,000
• Free Float: 132,365,000
• Market Cap: $39.29 billion
• Optionable: Optionable
• Beta: 0.31